S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13

Assembly Biosciences Stock Forecast, Price & News

-0.15 (-6.58%)
(As of 12/3/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
943,604 shs
Average Volume
1.33 million shs
Market Capitalization
$101.94 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ASMB News and Ratings via Email

Sign-up to receive the latest news and ratings for Assembly Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Assembly Biosciences logo

About Assembly Biosciences

Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses in two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate. The company was founded by Uri Lopatin and Derek A. Small on October 7, 2005 and is headquartered in South San Francisco, CA.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$79.11 million
Book Value
$4.69 per share


Net Income
$-62.15 million
Pretax Margin




Free Float
Market Cap
$101.94 million

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)

Social Links


Overall MarketRank

1.92 out of 5 stars

Medical Sector

563rd out of 1,390 stocks

Pharmaceutical Preparations Industry

263rd out of 668 stocks

Analyst Opinion: 3.2Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Assembly Biosciences (NASDAQ:ASMB) Frequently Asked Questions

Is Assembly Biosciences a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Assembly Biosciences in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Assembly Biosciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ASMB, but not buy additional shares or sell existing shares.
View analyst ratings for Assembly Biosciences
or view top-rated stocks.

How has Assembly Biosciences' stock been impacted by Coronavirus?

Assembly Biosciences' stock was trading at $15.60 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ASMB stock has decreased by 86.3% and is now trading at $2.13.
View which stocks have been most impacted by COVID-19

Are investors shorting Assembly Biosciences?

Assembly Biosciences saw a increase in short interest in the month of October. As of October 29th, there was short interest totaling 1,400,000 shares, an increase of 23.9% from the October 14th total of 1,130,000 shares. Based on an average daily trading volume, of 655,000 shares, the days-to-cover ratio is presently 2.1 days.
View Assembly Biosciences' Short Interest

When is Assembly Biosciences' next earnings date?

Assembly Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Assembly Biosciences

How were Assembly Biosciences' earnings last quarter?

Assembly Biosciences, Inc. (NASDAQ:ASMB) posted its quarterly earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($0.41) EPS for the quarter, topping the Zacks' consensus estimate of ($0.57) by $0.16. The biopharmaceutical company had revenue of $6.25 million for the quarter.
View Assembly Biosciences' earnings history

What price target have analysts set for ASMB?

5 equities research analysts have issued 1 year price objectives for Assembly Biosciences' stock. Their forecasts range from $3.10 to $15.00. On average, they anticipate Assembly Biosciences' share price to reach $8.32 in the next twelve months. This suggests a possible upside of 290.6% from the stock's current price.
View analysts' price targets for Assembly Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Assembly Biosciences' key executives?

Assembly Biosciences' management team includes the following people:
  • John G. McHutchison, President, Chief Executive Officer & Director (LinkedIn Profile)
  • Jason A. Okazaki, Chief Operating Officer
  • Michael P. Samar, Chief Financial & Accounting Officer
  • Luisa M. Stamm, Chief Medical Officer
  • Michele Anderson, Senior Vice President-Development Operations

What is John McHutchison's approval rating as Assembly Biosciences' CEO?

5 employees have rated Assembly Biosciences CEO John McHutchison on Glassdoor.com. John McHutchison has an approval rating of 80% among Assembly Biosciences' employees.

What other stocks do shareholders of Assembly Biosciences own?

What is Assembly Biosciences' stock symbol?

Assembly Biosciences trades on the NASDAQ under the ticker symbol "ASMB."

Who are Assembly Biosciences' major shareholders?

Assembly Biosciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.12%), Candriam Luxembourg S.C.A. (3.07%), Hudson Bay Capital Management LP (1.78%), Franklin Resources Inc. (1.22%), Geode Capital Management LLC (1.10%) and Dimensional Fund Advisors LP (0.75%). Company insiders that own Assembly Biosciences stock include Jacqueline Sybil Papkoff, John G Mchutchison, Luisa M Stamm, Richard James Colonno, Timothy A Springer and William E Iv Delaney.
View institutional ownership trends for Assembly Biosciences

Which institutional investors are selling Assembly Biosciences stock?

ASMB stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Advisers LP, Millennium Management LLC, Renaissance Technologies LLC, Dimensional Fund Advisors LP, Goldman Sachs Group Inc., Morgan Stanley, Caption Management LLC, and Citadel Advisors LLC. Company insiders that have sold Assembly Biosciences company stock in the last year include Jacqueline Sybil Papkoff, John G Mchutchison, and William E Iv Delaney.
View insider buying and selling activity for Assembly Biosciences
or view top insider-selling stocks.

Which institutional investors are buying Assembly Biosciences stock?

ASMB stock was purchased by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Eversept Partners LP, Prosight Management LP, Hudson Bay Capital Management LP, BlackRock Inc., Franklin Resources Inc., Geode Capital Management LLC, and Barclays PLC.
View insider buying and selling activity for Assembly Biosciences
or or view top insider-buying stocks.

How do I buy shares of Assembly Biosciences?

Shares of ASMB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Assembly Biosciences' stock price today?

One share of ASMB stock can currently be purchased for approximately $2.13.

How much money does Assembly Biosciences make?

Assembly Biosciences has a market capitalization of $101.94 million and generates $79.11 million in revenue each year. The biopharmaceutical company earns $-62.15 million in net income (profit) each year or ($2.76) on an earnings per share basis.

How many employees does Assembly Biosciences have?

Assembly Biosciences employs 139 workers across the globe.

When was Assembly Biosciences founded?

Assembly Biosciences was founded in 2005.

What is Assembly Biosciences' official website?

The official website for Assembly Biosciences is www.assemblybio.com.

Where are Assembly Biosciences' headquarters?

How can I contact Assembly Biosciences?

Assembly Biosciences' mailing address is 331 OYSTER POINT BOULEVARD FOURTH FLOOR, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at (833) 509-4583, via email at [email protected], or via fax at 646-706-5101.

This page was last updated on 12/4/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.